Oetzmann, Carolin http://orcid.org/0000-0003-1480-917X
White, Katie M.
Ivan, Alina
Julie, Jessica
Leightley, Daniel http://orcid.org/0000-0001-9512-752X
Lavelle, Grace http://orcid.org/0000-0003-3768-1797
Lamers, Femke
Siddi, Sara
Annas, Peter
Garcia, Sara Arranz
Haro, Josep Maria
Mohr, David C. http://orcid.org/0000-0002-5443-7596
Penninx, Brenda W. J. H.
Simblett, Sara K. http://orcid.org/0000-0002-8075-8238
Wykes, Til http://orcid.org/0000-0002-5881-8003
Narayan, Vaibhav A.
Hotopf, Matthew
Matcham, Faith
,
Article History
Received: 12 January 2022
Accepted: 22 August 2022
First Online: 3 September 2022
Competing interests
: M.H. is the principal investigator of the RADAR-CNS programme, a precompetitive public–private partnership funded by the Innovative Medicines Initiative and the European Federation of Pharmaceutical Industries and Associations. The programme receives support from Janssen, Biogen, MSD, UCB and Lundbeck. D.C.M. has accepted honoraria and consulting fees from Apple, Inc., Otsuka Pharmaceuticals, Pear Therapeutics, and the One Mind Foundation, royalties from Oxford Press, and has an ownership interest in Adaptive Health, Inc. P.A. is employed by the pharmaceutical company H. Lundbeck A/S. V.N. is an employee of Janssen Research & Development, LLC and hold company stocks/stock options. C.O. is supported by the UK Medical Research Council (MR/N013700/1) and King’s College London member of the MRC Doctoral Training Partnership in Biomedical Sciences. All other authors declare no competing interests.